BLOOD SUBSTITUTES
(See also Plasma Volume Expanders)
advantages over blood: g85 11/22 11; g65 7/22 11-12
alginon: g62 7/8 26; g60 3/8 30-31
“artificial blood”: w85 4/15 21; w83 11/1 23; w82 5/1 7; g82 6/22 26; g81 6/22 29-30; g80 2/22 21-23; g80 8/8 29-30; w79 11/15 29; g79 8/8 31; g79 10/8 29; g78 2/8 29; g74 6/22 22; g73 7/8 31; g72 6/22 29-30; g70 1/22 30; g70 2/8 30
advantages: g80 2/22 23; bq 53-55
blood substitute being developed at University of Pennsylvania’s School of Medicine: w85 4/15 21
Fluosol-DA discontinued: w85 4/15 21
Soviet Union: g81 2/22 29
use by Witnesses: w84 1/15 31; g80 2/8 29; g80 2/22 21, 23
Witness attitude toward: w84 1/15 31
capabilities: w61 565; bd 45-47
casein hydrolysate (CH):
under development in Australia: w85 4/15 21
coconut water: w55 523
comment by Brisbane, Australia, Daily Sun: g85 11/22 11
dextran: w84 1/15 31; bq 54; g65 7/22 12; g64 9/8 27; w63 535; bd 43, 46-47; g59 10/8 20; w56 509; g56 10/8 24; w55 439; w53 451; g52 9/22 8; g51 2/22 19; g50 8/8 12
gelatin: g65 7/22 11; bd 46; g51 2/22 18
haemaccel: bq 54; g63 6/22 29
hetastarch (hydroxyethyl starch): g82 6/22 26; bq 54
hormones: g57 12/8 24
lemon pectin: w55 523
necessary characteristics: g51 2/22 17
okra: g52 9/22 8
oral ferrous sulfate: w58 439
PVP (polyvinyl pyrrolidine): bq 54; g65 7/22 11; bd 46; g57 2/8 15; w55 492; g52 9/22 8; g51 6/8 31
Ringer’s lactate solution: w84 1/15 31; bq 54-56; g65 7/22 11
saline solution: bq 53-54; g65 7/22 11; bd 43, 45; g57 2/8 15; g51 2/22 17-18; g51 11/8 20; g50 8/8 11-12
Witness attitude toward: w84 1/15 31